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to the database and hopefully to raise the awareness of this disorder.Other
NDP074:
EXTRAPERITONEAL CYSTIC LYMPHANGIOMA WITH PRESENTATION OF
LOWER URINARY TRACT SYMPTOMS
Hsuan-Ying Ho, Kun-Hung Shen. Division of Urology, Department of
Surgery, Chi Mei Medical Center, Tainan, Taiwan
Case report: Extraperitoneal lymphangiomas are rare and usually
asymptomatic. The incidence retroperitoneal lymphangiomas is approxi-
mately 1%. The symptoms often depend on the location of the tumor and
the tumor size. We'd like to share a case in Chi-Mei hospital. A 47-year-old
man suffered from urinary frequency and nocturia for 2 years. The
symptoms worsened recently. Physical examination found low abdominal
dullness and palpable mass without tenderness. Sonography found post-
voiding residual urine 914ml. Abdominal CT showed a huge cystic lesion in
lower abdomen with compression to urinary bladder and bilateral ureter.
The patient then received surgical excision of the tumor. During the sur-
gery, a huge cystic lesion containing 3100cc ﬂuid with adhesion to urinary
bladder, left external iliac vessels, and obturator nerve was found, and was
removed smoothly. The post-operative pathology reported in cystic lym-
phangioma. The patient's post-operative condition remained ﬁne, and no
complication was noted.Oncology
NDP075:
LONG TERM HEALTH EFFECT OF ILEAL CONDUIT URINARY DIVERSION
Hao Lun Luo, Po Hui Chiang. Divisions of Urology, Department of Surgery,
Kaohsiung Chang Gung Medical Center, Kaohsiung, Taiwan
Purpose: Ileal conduit urinary diversion (ICUD) is the most common
procedure after radical cystectomy. Distributions of potential complica-
tions have been reported, but there is not adequate number of patients
with ICUD and bladder preservation control (transurethral resection of
bladder tumor, TURBT) for long-term follow-up duration. The aim of this
study is to compare the long-term health effect in patients who had un-
dergone ICUD during long term observation.
Materials and Methods: Data for this population-based cohort study
were obtained from the Taiwan National Health Insurance Research
Database (NHIRD). This study included 43,123 patients with diagnosis of
bladder cancer between 1997 and 2006. Only cancer-free patients
without chemotherapy and other types of urinary diversions and who
lived for longer than ﬁve years were included for analysis. All enrolled
subjects were followed-up until the end of 2011. The patients with
bladder cancer underwent ICUD after radical cystectomy or TURBT only
in this series.
Results: Compared to the patients who had undergone bladder preser-
vation procedure only, patients who had undergone ICUD after cystectomy
were noted to be independently associated with postoperative de novo
UTI, UTI with septicemia, and CKD (all the p < 0.001, HR ¼ 1.49, 5.02 and
3.07 respectively). The limitations of this study are its retrospective and
multicenter designs.
Conclusion: This study presents a nationwide cohort that ICUD after
radical cystectomy may cause higher incidence of UTI, UTI with septicemia
and CKD compared with TURBT only during long-term follow up.
NDP076:
LEAVING RESIDUAL URETERAL ORIFICE AFTER HAND-ASSISTED
RETROPERITONEOSCOPIC NEPHROURETERECTOMY FOR UPPER TRACT
UROTHELIAL CANCER IS LESS TIME CONSUMING AND DO NOT AFFECT
OVERALL SURVIVAL
Yu-Dan Chen, Wen-Horng Yang, Chien-Hui Ou. Department Of Urology,
National Cheng-Kung University Hospital, Medical College, National Cheng-
Kung University, Tainan, TaiwanPurpose: To determine the impact of residual ureteral oriﬁce after hand-
assisted retroperitoneoscopic nephroureterectomy (HARN) for primary
upper tract urothelial cancer (UTUC).
Materials and Methods:We retrospectively reviewed patients with upper
UTUC that had undergone HARN. Of these 75 patients, 37 of which
belonged to the study group with ipsilateral residual ureteral oriﬁce (RUO)
due to difﬁcult operative approach (because of obesity, previous pelvic
operation or radiation therapy, etc), while 38 patients served as controls
with no residual ureteral oriﬁce (NUO) postoperatively by follow up
cystoscopy. We analyzed intravesical recurrence, local recurrence, and
survival to assess the signiﬁcance between two groups.
Results: Baseline demographics were comparable in both groups. In
comparison with the RUO group, the NUO group was associated with a
longer total operative time (150± 78 vs.200± 115 mins, p ¼ 0.03). Bladder
recurrence was observed in 22 out of 37 (59.5%) in the RUO group and in 10
out of 38 (26%) in the NUO group (p ¼ 0.001) during median 39.7 months
follow up. There was a signiﬁcant difference in bladder cancer recurrence-
free rate in the NUO group versus RUO group (p ¼ 0.04). Forty-eight
percent (24/50) of ﬁrst intravesical recurrence had a tendency of recur-
rence occurring near the area of ipsilateral ureteral oriﬁce/scar especially
in RUO group (57.5% vs.40 %, p ¼ 0.04). Most patients (94%) in whom a
bladder tumor developed postoperatively were superﬁcial and underwent
transurethral resection of the bladder tumor. The survival rate was not
signiﬁcantly different when we compared the RUO and NUO groups
(p ¼ 0.42).
Conclusion: Leaving residual ureteral oriﬁce is less time consuming,
although increase the risk of intravesical recurrence, did not undermine
survival after HARN for primary UTUC.
NDP077:
COMPARISON OF CLINICAL PRACTICE GUIDELINES IN PROSTATE
CANCER BETWEEN JAPAN AND TAIWAN
Chih-Cheng Lu, Wen-Chou Fan, Tse-Chou Cheng. Division of Urology,
Department of Surgery, Chi Mei Medical Center, Liouying, Tainan
Purpose: This study is to compare the clinical practice guidelines in
managing prostate cancer (CaP) between Japan and Taiwan.
Materials and Methods: CPGs by Japanese Urological Association (JUA)
and Taiwan Cooperation Oncology Group (TCOG) were reviewed.
Results: Up to March 2015, the online guideline for CaP by JUA was
available since 2006 (updated in 2008).The latest CPG for CaP by TCOGwas
available in 2010 (the third edition since 1999). Neither JUA nor TCOG had
English version so far. JUA had a revised printed version published in April
2012. Evidence based medicine (EBM) was clearly applied by JUA but not
by TCOG. In diagnosis, MRI is not suggested before transrectal prostatic
biopsy in TCOG. The reference range of serum prostate speciﬁc antigen
(PSA) was based on Japanese people data with age speciﬁc consideration
by JUA, but was based on data from USA not from Taiwanese data by TCOG.
The age to start PSA checking was 55 years mentioned by JUA and 50 years
by TCOG. In treatment, watchful waiting therapy was more detailed by JUA
than by TCOG. Proton and heavy ion therapy were discussed in JUA but not
in TCOG. Chemoprevention of CaP was mentioned in JUA but not in TCOG.
Phytotherapy were not approved by JUA nor TCOG. For localized CaP, pri-
mary hormone therapy was recommended in JUA but not mentioned in
TCOG.
Conclusion: EBM is essential for modern CPGs. Variation exists between
Japanese and Taiwanese editions. From views of EBM, revision of Taiwa-
nese CPG for CaP is strongly suggested. Further study is needed to conﬁrm
these ﬁndings.
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BLADDER CANCER FOLLOWING NEPHROURETERECTOMY WITH
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COMPARING THE INCIDENCE BETWEEN SQUAMOUS CELL CARCINOMA
AND UROTHELIAL CARCINOMA
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